# Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection

> **NCT04608812** · PHASE1 · TERMINATED · sponsor: **OncoSynergy, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Glioma, Malignant
- High Grade Glioma
- Glioblastoma
- Glioblastoma Multiforme
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** OS2966
- **DRUG:** Gadoteridol

## Key facts

- **NCT ID:** NCT04608812
- **Lead sponsor:** OncoSynergy, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-02
- **Primary completion:** 2023-02-27
- **Final completion:** 2023-02-27
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Slow enrollment and financial constraints.
- **Last updated:** 2023-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608812, "Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04608812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*